GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Argent Biopharma Ltd (OTCPK:RGTLF) » Definitions » 3-Year Share Buyback Ratio

RGTLF (Argent Biopharma) 3-Year Share Buyback Ratio : -169.20% (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Argent Biopharma 3-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Argent Biopharma's current 3-Year Share Buyback Ratio was -169.20%.

The historical rank and industry rank for Argent Biopharma's 3-Year Share Buyback Ratio or its related term are showing as below:

RGTLF' s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -169.2   Med: -47.05   Max: -4
Current: -169.2

During the past 13 years, Argent Biopharma's highest 3-Year Share Buyback Ratio was -4.00%. The lowest was -169.20%. And the median was -47.05%.

RGTLF's 3-Year Share Buyback Ratio is ranked worse than
98.37% of 673 companies
in the Drug Manufacturers industry
Industry Median: -2.9 vs RGTLF: -169.20

Competitive Comparison of Argent Biopharma's 3-Year Share Buyback Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Argent Biopharma's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Argent Biopharma's 3-Year Share Buyback Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Argent Biopharma's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Argent Biopharma's 3-Year Share Buyback Ratio falls into.


;
;

Argent Biopharma 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Argent Biopharma (OTCPK:RGTLF) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Argent Biopharma 3-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of Argent Biopharma's 3-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Argent Biopharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Argent Biopharma Ltd (OTCPK:RGTLF) » Definitions » 3-Year Share Buyback Ratio
Comparable Companies
ASX:EOF ASX:IVX ASX:AGH ASX:EXL ASX:PER ASX:CAN ASX:BP8 ASX:ECS ASX:NXS ASX:LGP ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA
Traded in Other Exchanges
H5O0:Germany RGT:Australia
Address
295 Rokeby Road, Suite 1, Subiaco, WA, AUS, 6008
Website
https://www.argentbiopharma.com
Argent Biopharma Ltd is a drug discovery company that addresses unmet medical needs. The company focuses on multidisciplinary methods with nanotechnology, developing multi-target therapies for comprehensive disease management, especially in the central nervous system and immunology treatments. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury, and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others.